The Use of Slower-Acting (Class III) Symptom-Modifying Antirheumatic Drugs in Rheumatoid Arthritis

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Clinical Immunotherapeutics

• Publication date

  1996-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF03259329
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Minocycline in Rheumatoid Arthritis

  2012cited by this paper
• The European experience.

  2001cited by this paper
• Minocycline in Rheumatoid Arthritis: A 48-Week, Double-Blind, Placebo-Controlled Trial

  1995cited by this paper
• Refractory rheumatoid arthritis. Therapeutic options.

  1995cited by this paper
• Intermittent treatment with D-penicillamine is effective in lower doses and with fewer adverse effects in patients with rheumatoid arthritis.

  1994cited by this paper
• Guidelines for routine liver biopsy during methotrexate treatment.

  1994cited by this paper
• Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants.

  1994cited by this paper
• The mechanism of action of methotrexate in rheumatoid arthritis: the search continues.

  1994cited by this paper
• Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial.

  1994cited by this paper
• Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies).

  1994cited by this paper
• Methotrexate for Rheumatoid Arthritis

  1994cited by this paper
• Outcome in rheumatoid arthritis. A 1985 inception cohort study.

  1994cited by this paper
• Methotrexate for rheumatoid arthritis : suggested guidelines for monitoring liver toxicity

  1994cited by this paper
• Minocycline in Active Rheumatoid Arthritis

  1994cited by this paper
• Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. A multicenter randomized placebo-controlled trial.

  1994cited by this paper
• The future of biologics in the treatment of rheumatoid arthritis.

  1994cited by this paper
• Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

  1994cited by this paper
• Second-line drug therapy for rheumatoid arthritis.

  1994cited by this paper
• More evidence from a community based series of better outcome in rheumatoid arthritis. Data on the effect of multidisciplinary care on the retention of functional ability.

  1994cited by this paper
• The future of biologies in the treatment of rheumatoid arthritis

  1994cited by this paper
• The prospect for cytokine based therapeutic strategies in rheumatoid arthritis.

  1994cited by this paper
• Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group.

  1994cited by this paper
• Efficacy of additive DMARD therapy in patients with rheumatoid arthritis. Double blind controlled trial using bucillamine and placebo with maintenance doses of gold sodium thiomalate.

  1994cited by this paper
• Methotrexate: the emerging drug of choice for serious rheumatoid arthritis.

  1994cited by this paper
• Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate

  1993cited by this paper
• Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis.

  1993cited by this paper
• A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis.

  1993cited by this paper
• The curious case of intramuscular gold.

  1993cited by this paper
• Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial.

  1993cited by this paper
• Hydroxychloroquine Compared with Placebo in Rheumatoid Arthritis

  1993cited by this paper
• Mechanism of action of hydroxychloroquine as an antirheumatic drug.

  1993cited by this paper
• [Complications of immunosuppression].

  1993cited by this paper
• A unique presentation of multicentric reticulohistiocytosis in pregnancy.

  1993cited by this paper
• The relative toxicity of disease-modifying antirheumatic drugs.

  1993cited by this paper
• New classification of antirheumatic drugs. The evolution of a concept.

  1993cited by this paper
• Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial.

  1993cited by this paper
• Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

  1993cited by this paper
• The ocular safety of hydroxychloroquine.

  1993cited by this paper
• Risk for Sustained Amenorrhea in Patients with Systemic Lupus Erythematosus Receiving Intermittent Pulse Cyclophosphamide Therapy

  1993cited by this paper
• Early, aggressive therapy for rheumatoid arthritis: concerns, descriptions, and estimate of outcome.

  1993cited by this paper
• Combination therapy in rheumatoid arthritis--no benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy.

  1993cited by this paper
• Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone.

  1992cited by this paper
• Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial.

  1992cited by this paper
• Functional disability in rheumatoid arthritis: two different models in early and established disease.

  1992cited by this paper
• Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials.

  1992cited by this paper
• Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis

  1992cited by this paper
• Molecular mechanism of methotrexate action in inflammation

  1992cited by this paper
• Interaction of cyclosporine A and nonsteroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis.

  1992cited by this paper
• Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial.

  1992cited by this paper
• Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive synovial T cell clones derived from a patient with rheumatoid arthritis.

  1992cited by this paper
• PROGNOSTIC FACTORS FOR RADIOGRAPHIC DAMAGE AND PHYSICAL DISABILITY IN EARLY RHEUMATOID ARTHRITIS. A PROSPECTIVE FOLLOW-UP STUDY OF 147 PATIENTS

  1992cited by this paper
• A double-blind comparison of parenteral methotrexate and parenteral gold in the treatment of early erosive rheumatoid arthritis: an interim report on 102 patients after 12 months.

  1991cited by this paper
• Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis.

  1991cited by this paper
• Effect of parenterally administered gold therapy on the course of adult rheumatoid arthritis.

  1991cited by this paper
• Complications of immunosuppression associated with weekly low dose methotrexate.

  1991cited by this paper
• Long acting drug combinations in rheumatoid arthritis: a formal overview.

  1991cited by this paper
• Therapy for rheumatoid arthritis: combinations of disease-modifying drugs and new paradigms of treatment.

  1991cited by this paper
• Prognostic staging for therapy of rheumatoid arthritis.

  1991cited by this paper
• Rheumatic diseases and cancer.

  1991cited by this paper
• Rheumatic diseases and cancer.

  1991cited by this paper
• Suppression of collagen-induced arthritis by combination cyclosporin A and methotrexate therapy.

  1991cited by this paper
• Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis.

  1990cited by this paper
• Synergistic and additive effects of disease modifying anti-rheumatic drugs combined with chloroquine on the mitogen-driven stimulation of mononuclear cells.

  1990cited by this paper
• Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts.

  1990cited by this paper
• Combination therapy in rheumatoid arthritis.

  1990cited by this paper
• Reevaluating the therapeutic approach to rheumatoid arthritis: the "sawtooth" strategy.

  1990cited by this paper
• Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis.

  1990cited by this paper
• Anatomy and Human Movement: Structure and Function

  1990cited by this paper
• The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis.

  1990cited by this paper
• Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis.

  1990cited by this paper
• Remodeling the pyramid--a concept whose time has come.

  1989cited by this paper
• Intractable RA--treatment with combined methotrexate, azathioprine and hydroxychloroquine.

  1989cited by this paper
• Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: a prospective, randomized, placebo-controlled study.

  1989cited by this paper
• Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis.

  1989cited by this paper
• Combination methotrexate and sulfasalazine in the management of rheumatoid arthritis: case observations.

  1989cited by this paper
• Cyclosporin A binding to calmodulin.

  1989cited by this paper
• Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials.

  1988cited by this paper
• Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study.

  1988cited by this paper
• Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients.

  1988cited by this paper
• Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs?

  1988cited by this paper
• A long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three months.

  1988cited by this paper
• Combination chemotherapy in rheumatoid arthritis.

  1988cited by this paper
• Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis.

  1988cited by this paper
• Cyclosporin A in severe, treatment-refractory rheumatoid arthritis. A randomized study.

  1988cited by this paper
• Natural course of penicillamine nephropathy: a long term study of 33 patients

  1988cited by this paper
• Longterm followup of treatment with D-penicillamine for rheumatoid arthritis: effectivity and toxicity in relation to HLA antigens.

  1987cited by this paper
• Combined D-penicillamine and chloroquine treatment of rheumatoid arthritis--a comparative study.

  1987cited by this paper
• Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate.

  1987cited by this paper
• The in vivo effect of triethylphosphine gold (auranofin), sodium aurothiomalate and azathioprine on natural killer cell activity of patients with rheumatoid arthritis.

  1987cited by this paper
• Sulphasalazine alone or in combination with D-penicillamine in rheumatoid arthritis.

  1987cited by this paper
• Disability in rheumatoid arthritis: comparison of prognostic factors across three populations.

  1987cited by this paper
• Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells.

  1987cited by this paper
• Longterm followup of treatment with D-penicillamine for rheumatoid arthritis: effectivity and toxicity in relation to HLA antigens.

  1987cited by this paper
• Combination Therapy in Rheumatoid Arthritis—Study Design

  1987cited by this paper
• Penicillamine-induced proteinuria: risk factors.

  1986cited by this paper
• A three year follow up of patients allocated to placebo, or oral or injectable gold therapy for rheumatoid arthritis.

  1986cited by this paper
• Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression.

  1986cited by this paper
• The development of disability in rheumatoid arthritis.

  1986cited by this paper
• A study to determine the active moiety of sulphasalazine in rheumatoid arthritis.

  1986cited by this paper
• Low dose cytotoxic drug combination therapy in intractable rheumatoid arthritis two years later

  1986cited by this paper

• No citing papers are available for this paper.